Coactive Systems

Coactive Therapeutics is a biotechnology company pioneering a new class of medicines called 'Coactive' molecules. These bifunctional small molecules are designed to bridge the gap between proteins, enabling the modulation of protein-protein interactions (PPIs) that were previously considered undruggable. By leveraging its proprietary platform, the company aims to develop therapies for cancer and other serious diseases where traditional approaches have failed. Coactive's technology focuses on inducing proximity to either activate or inhibit target proteins in a highly specific manner, offering a versatile approach to precision medicine. The company is backed by top-tier investors and is currently in the pre-clinical stage of development.